?? Omics-Insights: Your Weekly Genomics & Proteomics Digest ??

Welcome to our latest Omics newsletter, your portal for the freshest updates and innovations in genomics. This week's newsletter brings you the latest updates from the dynamic world of Omics. In this edition, we bring you the latest developments in the dynamic world of Omics, including key industry news, strategic collaborations, skill development essentials for finding a new job, & essential career tips for omics professionals.

This week's latest news in the field of Omics:

?? Dovetail Genomics Partners With Goenomics for Enhanced Genome Annotation ??

Dovetail Genomics teamed up with Germany's Goenomics to improve genome assembly services. This partnership speeds up annotation for genomes up to 1 Gb, cutting the process down to three weeks. Customers will benefit from more accurate results and a complimentary enhanced analysis report. #genomics #biotech

?? BerGenBio Partners With Tempus for STK11-Mutant NSCLC Trial ??

BerGenBio is collaborating with Tempus to access real-world data for its NSCLC trial involving STK11 mutations. This data will help create a synthetic control arm and provide insights into patient responses. The trial aims to improve treatment outcomes using a combination of bemcentinib and Keytruda. #cancerresearch #clinicaltrials

?? Danaher Acquires Swiss Life Science Informatics Firm Genedata ??

Danaher acquired Swiss firm Genedata to strengthen its drug development tools. Genedata’s software automates and manages data processes in biopharma R&D, and this acquisition will help Danaher enhance its capabilities in accelerating therapy development. #biotech #pharmatech

?? Roche Invests $420M to Expand Chinese Diagnostics Facility ??

Roche is investing $420M to expand its diagnostics facility in Suzhou, China, to meet rising demand in the Asia-Pacific region. The expansion will boost production of PCR testing reagents and other diagnostic products. #diagnostics #healthcare

?? VION Biosciences Acquires Echelon Biosciences to Expand Specialty Lipids Offering ??

VION Biosciences acquired Echelon Biosciences, a leader in lipid nanoparticles, to enhance its drug discovery and manufacturing capabilities. This acquisition supports mRNA-based therapies and expands VION’s biopharmaceutical product portfolio. #biopharma #mrna

?? Ambry Genetics Launches ExomeReveal? Test for Rare Disease Detection ??

Ambry Genetics launched the ExomeReveal? test, which combines DNA and RNA analysis to improve rare disease detection. This test offers more accurate diagnoses, advancing patient care and treatment options. #genomics #raredisease

?? My Opinion on This Week's News:

Dovetail Genomics' partnership with Goenomics aims to enhance genome annotation services, leveraging advanced algorithms for faster and more accurate results, though the undisclosed financial terms leave some uncertainty.

BerGenBio's collaboration with Tempus introduces an innovative approach to clinical trials by using real-world data to establish a synthetic control arm, potentially setting a new standard for studies focused on STK11-mutant NSCLC.

Danaher's acquisition of Genedata underscores the growing importance of data management in biopharma, aligning with trends toward digitalization in drug development. Roche's $420M investment in expanding its diagnostics facility in China reflects the rising demand for healthcare solutions in Asia and could strengthen its market presence in the region.

VION Biosciences’ acquisition of Echelon Biosciences is a strategic move to bolster its position in the mRNA and gene therapy space, aligning with the increasing interest in personalized medicine. Lastly, Ambry Genetics' launch of the ExomeReveal test represents a significant leap in rare disease diagnostics, combining DNA and RNA analysis to improve diagnostic accuracy and patient outcomes.

Current Live Roles at Kinetica:

Account Manager – Proteomics - Belgium

Account Manager – Proteomics - Switzerland

Account Manager – Proteomics - Boston

Business Development Manager - Proteomics Reagents - DACH

Business Development Manager - Proteomics Reagents - USA

Account Manager – Mid-Atlantic – Genomics reagents

Sales Specialist - NGS - Boston

Director of Product Management - LS Capital Equipment - Europe

Director of Applications Support - Genomics - West Coast

Operation Manager - LS Reagents - UK

Field Service Engineer - Imaging Equipment - Benelux

Job Hunting Tips from an Omics Specialist Recruiter: The Pros and Cons of the "Open to Work" Banner on LinkedIn

As an Omics Specialist Recruiter, I often encounter job seekers grappling with the decision of whether to use the "Open to Work" banner on LinkedIn. Here’s a breakdown of the pros and cons to help you make an informed choice:

Pros:

1. Increased Visibility: The "Open to Work" banner signals to recruiters and hiring managers that you are actively seeking new opportunities. This can make your profile more visible in searches, leading to more job inquiries and connections. ????
2. Targeted Outreach: By indicating that you're open to new roles, you may receive more targeted job opportunities that match your skills and experience, potentially speeding up the job search process. ????
3. Networking Benefits: The banner can encourage your network to assist in your job search. Colleagues, industry connections, and recruiters who see the banner may share job leads or refer you to potential employers. ????
4. Clarity for Recruiters: It provides a clear message that you're available for new roles, helping recruiters quickly determine if you are a suitable candidate for their open positions. ???♂???

Cons:

1. Perceived Lack of Commitment: Some employers may perceive the banner as a sign of dissatisfaction or a lack of commitment to your current role, which could impact how they view your candidacy. ????
2. Privacy Concerns: If you’re currently employed and looking for a new job discreetly, the banner might alert your current employer or colleagues, which could be uncomfortable or detrimental to your current position. ????
3. Potential Overlook: Despite the increased visibility, there’s no guarantee that it will lead to more job offers. Recruiters may still overlook your profile if it doesn’t match their specific criteria or if they prefer candidates who are not actively broadcasting their job search. ????
4. Reduced Negotiation Leverage: Being openly available can sometimes reduce your negotiation power. Employers might view you as more eager and less inclined to negotiate on terms or salary. ????

Using the "Open to Work" banner can be a double-edged sword. It offers clear benefits in terms of visibility and networking, but also comes with potential downsides related to privacy and perceived commitment. Evaluate your current situation, including your job search strategy and privacy concerns, to decide if the banner aligns with your professional goals. If you choose to use it, make sure your profile is optimized to showcase your skills and achievements to attract the right opportunities. ???

#jobsearch #career #linkedin #professionaldevelopment

Wrapping Up Another Omics-Insights:

Thank you for embarking on a journey into the dynamic world of Omics with Kinetica! Explore the latest genomics job opportunities, stay informed with industry news, and indulge in insightful blogs at www.kinetica.co.uk. Your curiosity drives my commitment to relevant content, and I'm here to provide insights that fuel your scientific endeavors. Feel free to reach out with any questions or feedback. Wishing you ongoing inspiration and discovery in your scientific pursuits. Until next week, may your experiments yield groundbreaking results, and may your Omics journey remain as fascinating as the science itself!